|
1
|
Cun Y, Zhang Q, Xiong C, Li M, Dai N,
Zhang S and Wang D: Combined use of adenoviral vector
Ad5/F35-mediated APE1 siRNA enhances the therapeutic efficacy of
adenoviral-mediated p53 gene transfer in hepatoma cells in vitro
and in vivo. Oncol Rep. 29:2197–2204. 2013.PubMed/NCBI
|
|
2
|
Kim SY, Kang S, Song JJ and Kim JH: The
effectiveness of the oncolytic activity induced by Ad5/F35
adenoviral vector is dependent on the cumulative cellular
conditions of survival and autophagy. Int J Oncol. 42:1337–1348.
2013.PubMed/NCBI
|
|
3
|
Hu X, Cao Y, Meng Y and Hou M: A novel
modulation of structural and functional changes of mouse bone
marrow derived dendritic cells (BMDCs) by interleukin-2(IL-2). Hum
Vaccin Immunother. 11:516–521. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Vries IJ, Lesterhuis WJ, Scharenborg
NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM,
Torensma R, Adema GJ, et al: Maturation of dendritic cells is a
prerequisite for inducing immune responses in advanced melanoma
patients. Clin Cancer Res. 9:5091–5100. 2003.PubMed/NCBI
|
|
5
|
Kim R, Emi M and Tanabe K: Functional
roles of immature dendritic cells in impaired immunity of solid
tumour and their targeted strategies for provoking tumour immunity.
Clin Exp Immunol. 146:189–196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Castiello L, Sabatino M, Jin P, Clayberger
C, Marincola FM, Krensky AM and Stroncek DF: Monocyte-derived DC
maturation strategies and related pathways: A transcriptional view.
Cancer Immunol Immunother. 60:457–466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mossoba ME and Medin JA: Cancer
immunotherapy using virally transduced dendritic cells: Animal
studies and human clinical trials. Expert Rev Vaccines. 5:717–732.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cavallini C, Lovato O, Bertolaso A,
Pacelli L, Zoratti E, Zanolin E, Krampera M, Zamò A, Tecchio C,
Cassatella MA, et al: The TNF-family cytokine TL1A inhibits
proliferation of human activated B cells. PLoS One. 8:e601362013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Erdmann M and Schuler-Thurner B: Towards a
standardized protocol for the generation of monocyte-derived
dendritic cell vaccines. Methods Mol Biol. 595:149–163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Z, Liu H, He XP, Tan XH, Zhou Y, Chen
X, Shi YJ, Liu XD and Chen HR: A clinical study of cytokine-induced
killer cells for the treatment of refractory lymphoma. Oncol Lett.
2:531–536. 2011.PubMed/NCBI
|
|
11
|
Boudreau JE, Bonehill A, Thielemans K and
Wan Y: Engineering dendritic cells to enhance cancer immunotherapy.
Mol Ther. 19:841–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morelli AE, Zahorchak AF, Larregina AT,
Colvin BL, Logar AJ, Takayama T, Falo LD and Thomson AW: Cytokine
production by mouse myeloid dendritic cells in relation to
differentiation and terminal maturation induced by
lipopolysaccharide or CD40 ligation. Blood. 98:1512–1523. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kelleher M and Beverley PC:
Lipopolysaccharide modulation of dendritic cells is insufficient to
mature dendritic cells to generate CTLs from naive polyclonal
CD8+ T cells in vitro, whereas CD40 ligation is
essential. J Immunol. 167:6247–6255. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tcherepanova IY, Adams MD, Feng X,
Hinohara A, Horvatinovich J, Calderhead D, Healey D and Nicolette
CA: Ectopic expression of a truncated CD40L protein from synthetic
post-transcriptionally capped RNA in dendritic cells induces high
levels of IL-12 secretion. BMC Mol Biol. 9:902008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hernandez MG, Shen L and Rock KL:
CD40-CD40 ligand interaction between dendritic cells and
CD8+ T cells is needed to stimulate maximal T cell
responses in the absence of CD4+ T cell help. J Immunol.
178:2844–2852. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thacker EE, Nakayama M, Smith BF, Bird RC,
Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl
TD, et al: A genetically engineered adenovirus vector targeted to
CD40 mediates transduction of canine dendritic cells and promotes
antigen-specific immune responses in vivo. Vaccine. 27:7116–7124.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi T, Moore MA and Crystal RG:
Dendritic cells modified to express CD40 ligand elicit therapeutic
immunity against preexisting murine tumors. Blood. 96:91–99.
2000.PubMed/NCBI
|
|
18
|
Tada Y, O-Wang J, Yu L, Shimozato O, Wang
YQ, Takiguchi Y, Tatsumi K, Kuriyama T, Takenaga K, Sakiyama S, et
al: T-cell-dependent antitumor effects produced by CD40 ligand
expressed on mouse lung carcinoma cells are linked with the
maturation of dendritic cells and secretion of a variety of
cytokines. Cancer Gene Ther. 10:451–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wolf B, Schwarzer A, Côté AL, Hampton TH,
Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, et
al: Gene expression profile of peripheral blood lymphocytes from
renal cell carcinoma patients treated with IL-2, interferon-α and
dendritic cell vaccine. PLoS One. 7:e502212012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stax AM, Crul C, Kamerling SW, Schlagwein
N, van der Geest RN, Woltman AM and van Kooten C: CD40L stimulation
of rat dendritic cells specifically favors the IL-12/IL-10 ratio
resulting in a strong T cell stimulatory capacity. Mol Immunol.
45:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagy ZS, Ross JA, Rodriguez G, Balint BL,
Szeles L, Nagy L and Kirken RA: Genome wide mapping reveals PDE4B
as an IL-2 induced STAT5 target gene in activated human PBMCs and
lymphoid cancer cells. PLoS One. 8:e573262013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonzalez-Carmona MA, Lukacs-Kornek V,
Timmerman A, Shabani S, Kornek M, Vogt A, Yildiz Y, Sievers E,
Schmidt-Wolf IG, Caselmann WH, et al: CD40ligand-expressing
dendritic cells induce regression of hepatocellular carcinoma by
activating innate and acquired immunity in vivo. Hepatology.
48:157–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
DeBenedette MA, Calderhead DM,
Tcherepanova IY, Nicolette CA and Healey DG: Potency of mature
CD40L RNA electroporated dendritic cells correlates with IL-12
secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic
T-cell responses in vitro. J Immunother. 34:45–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rousseau RF, Biagi E, Dutour A, Yvon ES,
Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, et al:
Immunotherapy of high-risk acute leukemia with a recipient
(autologous) vaccine expressing transgenic human CD40L and IL-2
after chemotherapy and allogeneic stem cell transplantation. Blood.
107:1332–1341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Balamotis MA, Huang K and Mitani K:
Efficient delivery and stable gene expression in a hematopoietic
cell line using a chimeric serotype 35 fiber pseudotyped
helper-dependent adenoviral vector. Virology. 324:229–237. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gaggar A, Shayakhmetov DM and Lieber A:
CD46 is a cellular receptor for group B adenoviruses. Nat Med.
9:1408–1412. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ophorst OJ, Kostense S, Goudsmit J, De
Swart RL, Verhaagh S, Zakhartchouk A, Van Meijer M, Sprangers M,
Van Amerongen G, Yüksel S, et al: An adenoviral type 5 vector
carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross
neutralization, and immunogenicity. Vaccine. 22:3035–3044. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vitoriano-Souza J, Moreira N,
Teixeira-Carvalho A, Carneiro CM, Siqueira FA, Vieira PM,
Giunchetti RC, Moura SA, Fujiwara RT, Melo MN, et al: Cell
recruitment and cytokines in skin mice sensitized with the vaccine
adjuvants: Saponin, incomplete Freund's adjuvant, and
monophosphoryl lipid A. PLoS One. 7:e407452012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard
L, Yu Z, Zheng Z, Jones S, Restifo NP, Rosenberg SA, et al:
Development of optimal bicistronic lentiviral vectors facilitates
high-level TCR gene expression and robust tumor cell recognition.
Gene Ther. 15:1411–1423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ngoi SM, Chien AC and Lee CG: Exploiting
internal ribosome entry sites in gene therapy vector design. Curr
Gene Ther. 4:15–31. 2004. View Article : Google Scholar : PubMed/NCBI
|
